{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:05:39Z","timestamp":1791821139981,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2018092 and 2021091"],"award-info":[{"award-number":["2018092 and 2021091"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regional Inflammation Research Network"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with HBeAg-negative chronic hepatitis B may experience an immune response after stopping nucleos(t)ide analogue (NA)therapy, which may potentially trigger HBsAg loss or off-therapy sustained viral control. The immunological mechanisms determining clinical response remain poorly understood. To identify inflammatory signatures associated with defined outcomes, we analysed plasma cytokines and chemokines from 57 HBeAg-negative patients enrolled in the Nuc-Stop Study at baseline and 12\u00a0weeks after NA cessation. Clinical response at 12\u00a0weeks was classified into four groups: immune control, viral relapse, evolving clinical relapse, and resolving clinical relapse. Twelve weeks after treatment cessation 17 patients (30%) experienced immune control, 19 (33%) viral relapse, 6 (11%) evolving clinical relapse, and 15 (26%) resolving clinical relapse. There was a significant increase in interferon-\u03b3-induced protein 10 (IP-10; p\u2009=\u20090.012) and tumor necrosis factor (TNF; p\u2009=\u20090.032) in patients with evolving clinical relapse. Sparse partial least-squares multivariate analyses (sPLS-DA) showed higher first component values for the clinical relapse group compared to the other groups, separation was driven mainly by IP-10, TNF, IL-9, IFN-\u03b3, MIP-1\u03b2, and IL-12. Our results demonstrate that evolving clinical relapse after NA cessation is associated with a systemic increase in the proinflammatory cytokines IP-10 and TNF.<\/jats:p><jats:p><jats:italic>Clinical trial registration<\/jats:italic>: ClinicalTrials.gov, Identifier: NCT03681132.<\/jats:p>","DOI":"10.1038\/s41598-023-50216-y","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T10:03:00Z","timestamp":1702980180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment cessation in\u00a0HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines"],"prefix":"10.1038","volume":"13","author":[{"given":"Marte","family":"Holmberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian D.","family":"Aass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dalgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Samuelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas K.","family":"Bj\u00f6rkstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgeir","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag Henrik","family":"Reikvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"50216_CR1","unstructured":"WHO. Hepatitis B Fact sheet 2020, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b (2020)."},{"key":"50216_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/s0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po, C., Chan, H. L. & Lok, A. Hepatitis B virus infection. Lancet 384, 2053\u20132063. https:\/\/doi.org\/10.1016\/s0140-6736(14)60220-8 (2014).","journal-title":"Lancet"},{"key":"50216_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/s1473-3099(16)30204-3","volume":"16","author":"S Nayagam","year":"2016","unstructured":"Nayagam, S. et al. Requirements for global elimination of hepatitis B: A modelling study. Lancet Infect. Dis. 16, 1399\u20131408. https:\/\/doi.org\/10.1016\/s1473-3099(16)30204-3 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"50216_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s2468-1253(22)00124-8","volume":"7","author":"GHB Collaborators","year":"2022","unstructured":"Collaborators, G. H. B. Global, regional, and national burden of hepatitis B, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7, 796\u2013829. https:\/\/doi.org\/10.1016\/s2468-1253(22)00124-8 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"50216_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","volume":"68","author":"WJ Jeng","year":"2018","unstructured":"Jeng, W. J., Chen, Y. C., Chien, R. N., Sheen, I. S. & Liaw, Y. F. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology 68, 425\u2013434. https:\/\/doi.org\/10.1002\/hep.29640 (2018).","journal-title":"Hepatology"},{"key":"50216_CR6","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim, G. A. et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability. Gut 63, 1325\u20131332. https:\/\/doi.org\/10.1136\/gutjnl-2013-305517 (2014).","journal-title":"Gut"},{"key":"50216_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra2211764","volume":"388","author":"G Dusheiko","year":"2023","unstructured":"Dusheiko, G., Agarwal, K. & Maini, M. K. New approaches to chronic hepatitis B. N. Engl. J. Med. 388, 55\u201369. https:\/\/doi.org\/10.1056\/NEJMra2211764 (2023).","journal-title":"N. Engl. J. Med."},{"key":"50216_CR8","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","volume":"224","author":"YC Hsu","year":"2021","unstructured":"Hsu, Y. C. et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J. Infect. Dis. 224, 1890\u20131899. https:\/\/doi.org\/10.1093\/infdis\/jiab241 (2021).","journal-title":"J. Infect. Dis."},{"key":"50216_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","volume":"143","author":"SJ Hadziyannis","year":"2012","unstructured":"Hadziyannis, S. J., Sevastianos, V., Rapti, I., Vassilopoulos, D. & Hadziyannis, E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143, 629-636.e621. https:\/\/doi.org\/10.1053\/j.gastro.2012.05.039 (2012).","journal-title":"Gastroenterology"},{"key":"50216_CR10","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","volume":"76","author":"MJ Sonneveld","year":"2022","unstructured":"Sonneveld, M. J. et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J. Hepatol. 76, 1042\u20131050. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.007 (2022).","journal-title":"J. Hepatol."},{"key":"50216_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/gutjnl-2020-323979","volume":"71","author":"SAL Hall","year":"2022","unstructured":"Hall, S. A. L. et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: A meta-analysis. Gut 71, 1629\u20131641. https:\/\/doi.org\/10.1136\/gutjnl-2020-323979 (2022).","journal-title":"Gut"},{"key":"50216_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/apt.16968","volume":"56","author":"SAL Hall","year":"2022","unstructured":"Hall, S. A. L. et al. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels. Aliment. Pharmacol. Ther. 56, 310\u2013320. https:\/\/doi.org\/10.1111\/apt.16968 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"50216_CR13","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","volume":"68","author":"KS Liem","year":"2019","unstructured":"Liem, K. S. et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: Results from a randomised controlled trial (Toronto STOP study). Gut 68, 2206\u20132213. https:\/\/doi.org\/10.1136\/gutjnl-2019-318981 (2019).","journal-title":"Gut"},{"key":"50216_CR14","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","volume":"214","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen, C. et al. Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J. Infect. Dis. 214, 1492\u20131497. https:\/\/doi.org\/10.1093\/infdis\/jiw412 (2016).","journal-title":"J. Infect. Dis."},{"key":"50216_CR15","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"T Berg","year":"2017","unstructured":"Berg, T. et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients: Finite study. J. Hepatol. 67, 918\u2013924. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.012 (2017).","journal-title":"J. Hepatol."},{"key":"50216_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","volume":"222","author":"R Fan","year":"2020","unstructured":"Fan, R. et al. Combining hepatitis B virus RNA and hepatitis B core-related antigen: Guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B. J. Infect. Dis. 222, 611\u2013618. https:\/\/doi.org\/10.1093\/infdis\/jiaa136 (2020).","journal-title":"J. Infect. Dis."},{"key":"50216_CR17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","volume":"78","author":"F van Bommel","year":"2023","unstructured":"van Bommel, F. et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J. Hepatol. 78, 926\u2013936. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.018 (2023).","journal-title":"J. Hepatol."},{"key":"50216_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031407","author":"C Liu","year":"2022","unstructured":"Liu, C., Shih, Y. F. & Liu, C. J. Immunopathogenesis of acute flare of chronic hepatitis B: With emphasis on the role of cytokines and chemokines. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23031407 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"50216_CR19","doi-asserted-by":"publisher","first-page":"S1150","DOI":"10.1016\/S0168-8278(23)03285-3","volume":"78","author":"A Johannessen","year":"2023","unstructured":"Johannessen, A. et al. The Nuc-Stop study: An open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients. J. Hepatol. 78, S1150\u2013S1151. https:\/\/doi.org\/10.1016\/S0168-8278(23)03285-3 (2023).","journal-title":"J. Hepatol."},{"key":"50216_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","journal-title":"J. Hepatol."},{"key":"50216_CR21","doi-asserted-by":"publisher","first-page":"e1005752","DOI":"10.1371\/journal.pcbi.1005752","volume":"13","author":"F Rohart","year":"2017","unstructured":"Rohart, F., Gautier, B., Singh, A. & L\u00ea Cao, K.-A. mixOmics: An R package for \u2018omics feature selection and multiple data integration. PLoS Comput. Biol. 13, e1005752\u2013e1005752. https:\/\/doi.org\/10.1371\/journal.pcbi.1005752 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"50216_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122268","author":"S Yoshio","year":"2018","unstructured":"Yoshio, S. et al. Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.122268 (2018).","journal-title":"JCI Insight"},{"key":"50216_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/hep4.1626","volume":"5","author":"M W\u00fcbbolding","year":"2021","unstructured":"W\u00fcbbolding, M. et al. Pilot study using machine learning to identify immune profiles for the prediction of early virological relapse after stopping nucleos(t)ide analogues in HBeAg-negative CHB. Hepatol. Commun. 5, 97\u2013111. https:\/\/doi.org\/10.1002\/hep4.1626 (2021).","journal-title":"Hepatol. Commun."},{"key":"50216_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac375","author":"SA Hall","year":"2022","unstructured":"Hall, S. A. et al. Hepatitis B virus flares following nucleot(s)ide analogue cessation are associated with activation of TLR signalling pathways. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiac375 (2022).","journal-title":"J. Infect. Dis."},{"key":"50216_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.805625","volume":"8","author":"S Zhong","year":"2021","unstructured":"Zhong, S., Zhang, T., Tang, L. & Li, Y. Cytokines and chemokines in HBV infection. Front. Mol. Biosci. 8, 805625. https:\/\/doi.org\/10.3389\/fmolb.2021.805625 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"50216_CR26","doi-asserted-by":"publisher","first-page":"40404","DOI":"10.1038\/srep40404","volume":"7","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Predictive value of serum IFN-gamma inducible protein-10 and IFN-gamma\/IL-4 ratio for liver fibrosis progression in CHB patients. Sci. Rep. 7, 40404. https:\/\/doi.org\/10.1038\/srep40404 (2017).","journal-title":"Sci. Rep."},{"key":"50216_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cytogfr.2011.06.001","volume":"22","author":"M Liu","year":"2011","unstructured":"Liu, M. et al. CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22, 121\u2013130. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.06.001 (2011).","journal-title":"Cytokine Growth Factor Rev."},{"key":"50216_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jhep.2009.12.015","volume":"52","author":"AT Tan","year":"2010","unstructured":"Tan, A. T. et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J. Hepatol. 52, 330\u2013339. https:\/\/doi.org\/10.1016\/j.jhep.2009.12.015 (2010).","journal-title":"J. Hepatol."},{"key":"50216_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/apt.13447","volume":"43","author":"GL Wong","year":"2016","unstructured":"Wong, G. L. et al. Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 43, 145\u2013153. https:\/\/doi.org\/10.1111\/apt.13447 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"50216_CR30","doi-asserted-by":"publisher","first-page":"14118","DOI":"10.1038\/s41598-019-50729-5","volume":"9","author":"SB Wiegand","year":"2019","unstructured":"Wiegand, S. B. et al. Soluble immune markers in the different phases of chronic hepatitis B virus infection. Sci. Rep. 9, 14118. https:\/\/doi.org\/10.1038\/s41598-019-50729-5 (2019).","journal-title":"Sci. Rep."},{"key":"50216_CR31","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/hep.29348","volume":"66","author":"X Cheng","year":"2017","unstructured":"Cheng, X. et al. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology 66, 1779\u20131793. https:\/\/doi.org\/10.1002\/hep.29348 (2017).","journal-title":"Hepatology"},{"key":"50216_CR32","doi-asserted-by":"publisher","first-page":"105231","DOI":"10.1016\/j.micpath.2021.105231","volume":"161","author":"M Barathan","year":"2021","unstructured":"Barathan, M. et al. Comparative expression of pro-inflammatory and apoptotic biosignatures in chronic HBV-infected patients with and without liver cirrhosis. Microb. Pathog. 161, 105231\u2013105231. https:\/\/doi.org\/10.1016\/j.micpath.2021.105231 (2021).","journal-title":"Microb. Pathog."},{"key":"50216_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2019.08.024","volume":"72","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. TNF-\u03b1\/IFN-\u03b3 profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J. Hepatol. 72, 45\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.024 (2020).","journal-title":"J. Hepatol."},{"key":"50216_CR34","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","volume":"16","author":"MP Pauly","year":"2018","unstructured":"Pauly, M. P. et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin. Gastroenterol. Hepatol. 16, 1964-1973.e1961. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.033 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"50216_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","volume":"69","author":"F Rinker","year":"2018","unstructured":"Rinker, F. et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J. Hepatol. 69, 584\u2013593. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.004 (2018).","journal-title":"J. Hepatol."},{"key":"50216_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4049\/jimmunol.1401659","volume":"194","author":"JF Wu","year":"2015","unstructured":"Wu, J. F. et al. The effects of cytokines on spontaneous hepatitis B surface antigen seroconversion in chronic hepatitis B virus infection. J. Immunol. 194, 690\u2013696. https:\/\/doi.org\/10.4049\/jimmunol.1401659 (2015).","journal-title":"J. Immunol."},{"key":"50216_CR37","unstructured":"Murphy, K., Weaver, C. T., Berg, L. & Janeway, C. A. Janeway's immunobiology. 10th edition \/ Kenneth Murphy, Casey Weaver, Leslie Berg; with contribution by Gregory Barton.; International student edition. edn, (W.W. Norton and Company, 2022)."},{"key":"50216_CR38","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3748\/wjg.v19.i7.1104","volume":"19","author":"XZ Duan","year":"2013","unstructured":"Duan, X. Z. et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J. Gastroenterol. 19, 1104\u20131110. https:\/\/doi.org\/10.3748\/wjg.v19.i7.1104 (2013).","journal-title":"World J. Gastroenterol."},{"key":"50216_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885829","volume":"13","author":"J Tong","year":"2022","unstructured":"Tong, J. et al. Granulocyte colony-stimulating factor accelerates the recovery of hepatitis B virus-related acute-on-chronic liver failure by promoting M2-like transition of monocytes. Front. Immunol. 13, 885829. https:\/\/doi.org\/10.3389\/fimmu.2022.885829 (2022).","journal-title":"Front. Immunol."},{"key":"50216_CR40","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jhep.2021.07.033","volume":"75","author":"C Engelmann","year":"2021","unstructured":"Engelmann, C. et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). J. Hepatol. 75, 1346\u20131354. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.033 (2021).","journal-title":"J. Hepatol."},{"key":"50216_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s2468-1253(19)30344-9","volume":"5","author":"MG Ghany","year":"2020","unstructured":"Ghany, M. G. et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: The good and the bad. Lancet Gastroenterol. Hepatol. 5, 406\u2013417. https:\/\/doi.org\/10.1016\/s2468-1253(19)30344-9 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"50216_CR42","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/infdis\/jiab596","volume":"225","author":"CH Chen","year":"2022","unstructured":"Chen, C. H. et al. Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in hepatitis B e antigen-positive patients. J. Infect. Dis. 225, 1974\u20131981. https:\/\/doi.org\/10.1093\/infdis\/jiab596 (2022).","journal-title":"J. Infect. Dis."},{"key":"50216_CR43","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","volume":"218","author":"C H\u00f6ner Zu Siederdissen","year":"2018","unstructured":"H\u00f6ner Zu Siederdissen, C. et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients. J. Infect. Dis. 218, 1480\u20131484. https:\/\/doi.org\/10.1093\/infdis\/jiy350 (2018).","journal-title":"J. Infect. Dis."},{"key":"50216_CR44","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/infdis\/jix690","volume":"217","author":"TH Su","year":"2018","unstructured":"Su, T. H. et al. Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy. J. Infect. Dis. 217, 1193\u20131201. https:\/\/doi.org\/10.1093\/infdis\/jix690 (2018).","journal-title":"J. Infect. Dis."},{"key":"50216_CR45","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/liv.15140","volume":"42","author":"YC Liu","year":"2022","unstructured":"Liu, Y. C., Jeng, W. J., Peng, C. W., Chien, R. N. & Liaw, Y. F. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. Liver Int. 42, 551\u2013560. https:\/\/doi.org\/10.1111\/liv.15140 (2022).","journal-title":"Liver Int."},{"key":"50216_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17602","author":"C-H Chen","year":"2023","unstructured":"Chen, C.-H. et al. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Aliment. Pharmacol. Ther. https:\/\/doi.org\/10.1111\/apt.17602 (2023).","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50216-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50216-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50216-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T14:08:56Z","timestamp":1703254136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50216-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["50216"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50216-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22590"}}